Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02383758 · ClinicalTrials.gov registry record · NA
An Interdisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT02383758: Completed NA study, sponsored by Emory University.
NCT02383758 is a NA study that has completed, run by Emory University. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02383758, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to try to treat bowel movement (BM) accidents differently with children with autism spectrum disorder (ASD). The study will use over-the-counter (OTC) medications to evoke predictable bowel movements. This will make it possible for investigators to use certain strategies to reward BMs in the toilet. Independence will be increased by fading out the use of medications. The investigators will also train caregivers to implement the procedures.
Primary Outcome
The percentage of participant's with continent bowel movements (control of passage of stool from the bowel).
Interventions
- DRUG Senna
- DRUG Glycerin Suppository
- DRUG Bisacodyl suppository
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-02-01 |
| Est. Completion | 2017-01-01 |
| Phase | NA |
What the finished NCT02383758 record still lists
NCT02383758 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Senna is the first listed.
NCT02383758 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02383758 about?
NCT02383758 is a clinical study titled "An Interdisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders". The purpose of this study is to try to treat bowel movement (BM) accidents differently with children with autism spectrum disorder (ASD). The study will use over-the-counter (OTC) medications to evoke predictable bowel movements. This will make it possible for investigators to use certain strategies...
What is the current status of trial NCT02383758?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2015-02-01. Estimated completion is 2017-01-01.
What interventions are being tested in trial NCT02383758?
The interventions under investigation include: Senna (DRUG), Glycerin Suppository (DRUG), Bisacodyl suppository (DRUG).
Who is sponsoring clinical trial NCT02383758?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02383758's enrollment target sits among peer trials
22 1756th of 2000 higher than 239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI